Eisai And Daiichi Sankyo To Strengthen In-house R&D Capabilities
This article was originally published in PharmAsia News
Executive Summary
To strengthen research and development capability, Eisai will establish quasi-venture enterprise units inside the company. The units will conduct new drug discovery and product commercialization. The move is aimed to reorganize the company's domestic and overseas research staff in oncology and other areas and speed up new drug development. Along the same lines, Daiichi Sankyo will utilize Ranbaxy's research facilities and expand its R&D capabilities. (Click here for more - Japanese language
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.